Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025

Alkermes plc (ALKS) has emerged as a leading player in the psychedelic stock market, with its innovative pipeline of orexin 2 receptor agonists, such as ALKS 2680, positioning the company at the forefront of the neuroscience market. As investors seek to capitalize on the growing potential of psychedelic stocks, Alkermes stands out as an attractive investment opportunity in 2025.

Alkermes' strategic focus on central disorders of hypersomnolence, including narcolepsy and idiopathic hypersomnia, addresses a significant unmet medical need. The company's proprietary technology and intellectual property portfolio, combined with its promising clinical data, set the stage for potential success in the competitive landscape. With a strong pipeline and a commitment to neuroscience research, Alkermes is well-positioned to unlock the multi-billion-dollar market opportunity for orexin 2 receptor agonists.

Key factors driving Alkermes' potential success include:

1. Unmet medical need: Central disorders of hypersomnolence are chronic, debilitating conditions with limited treatment options. ALKS 2680 addresses this unmet medical need by targeting the underlying cause of excessive daytime sleepiness and disrupted sleep-wake cycles.
2. Disease prevalence: Narcolepsy, for instance, affects approximately 1 in 2,000 people in the United States, with a significant portion of patients remaining undiagnosed. Idiopathic hypersomnia, although less common, also has a substantial patient population. These prevalence numbers, combined with the chronic nature of the diseases, create a large market opportunity for ALKS 2680.
3. Competitive landscape: The current market for narcolepsy and idiopathic hypersomnia treatments is dominated by stimulants, which have limited efficacy and significant side effects. ALKS 2680's novel mechanism of action, targeting the orexin system, sets it apart from existing treatments and offers the potential for improved efficacy and safety.
4. Clinical data: Alkermes' phase 2 studies for ALKS 2680 in narcolepsy type 1 and type 2 have shown promising results, with data expected in the second half of 2025. Positive clinical data will further validate the potential of ALKS 2680 and strengthen Alkermes' position in the market.
5. Intellectual property: Alkermes' proprietary technology and intellectual property portfolio, including its orexin 2 receptor agonists, provide the company with a competitive advantage and protect its products from generic competition.



In conclusion, Alkermes plc (ALKS) is among the best psychedelic stocks to buy in 2025, given its strong pipeline of orexin 2 receptor agonists, strategic focus on central disorders of hypersomnolence, and commitment to neuroscience research. With a compelling value proposition and a competitive advantage in the market, Alkermes is well-positioned to capitalize on the growing potential of the psychedelic stock market. As investors seek to capitalize on this opportunity, Alkermes stands out as an attractive investment option in 2025.